Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, including sales of the subcutaneous product, as reported by Johnson & Johnson (JNJ) were $7.977B in 2022. Net trade sales were $4.21B in the U.S. and $3.767B in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GMAB:
- Grant of Restricted Stock Units and Warrants to Employees in Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
- Genmab price target raised to DKK 3,600 from DKK 3,450 at JPMorgan
- Genmab submits JNDA for epcoritamab to treat patients with R/R LBCL
- Genmab downgraded to Neutral at Citi with risk/reward ‘more balanced’ for 2023